Loading…
← CockpitCompetitor Analysis › 300255.SZ Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A300255.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Makes heparin products, from crude heparin and heparin-sodium raw material to enoxaparin and other low-molecular-weight heparin injections.

Momentum laggard 4
Mkt cap
$2.33B
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$50.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-12.5 pp
WACC 8.7%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥17.22
1D-1.0%
1W-13.7%
1M-14.5%
3M-39.3%
6M-58.9%
YTD-72.3%
1Y-69.2%
ATR %5.4%
52w lowhigh75.4% off high

What Hebei Changshan Biochemical Pharmaceutical does

Makes heparin products, from crude heparin and heparin-sodium raw material to enoxaparin and other low-molecular-weight heparin injections.

Sells heparin, an anticoagulant drawn from pig intestines, in raw and finished forms: crude heparin, pharmaceutical-grade active ingredient, and low-molecular-weight heparin injections such as enoxaparin and dalteparin. Raw material and injections are the main income sources, with exports to Europe and the US a stated growth push and hospital sales set by China's bulk-purchase tenders.

Products and services

  • Crude heparin sodium
  • Heparin sodium and LMWH active ingredients
  • Enoxaparin sodium injection
  • Dalteparin and other LMWH injections

Customers

  • Hospitals via China's volume-based purchasing
  • Overseas generic and API buyers in Europe and the
  • Export markets in Central Asia, Pakistan and Afric

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Heparin raw materials and…

What could go right

  • Heparin exports to Europe and the US
  • New heparin API capacity coming online

What could go wrong

  • China volume-based procurement price pressure
  • Pig-intestine raw-material supply and price swings

Moat: narrow (regulatory licence, customer qualification). Holds several LMWH approvals and EU GMP certification for enoxaparin and heparin raw materials.

Headquarters: Shijiazhuang, China · Founded: 2000 · Employees: 1,194

Named competitors

Hebei Changshan Biochemical Pharmaceutical at a glance

Size Hebei Changshan Biochemical Pharmaceutical (300255.SZ) is a China Health Care company (Biotechnology) with a market value of $2.33B, the 1034th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.22 on 18 Nov 2026.

Performance Over six months the shares fell 58.9%, against -10.8% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 0.2% over the last twelve months (peer median +10.7%); the operating margin is -25.4% (peer median -13.6%).

Valuation It trades at 19.4× enterprise value to sales against a peer median of 9.4× (5th most expensive of 16).

Capital Return on invested capital runs 12.5 points below its cost of capital (8.7% WACC).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 92300255.SZ 41
Six months, rebased to 100: Hebei Changshan Biochemical Pharmaceutical against the median of its 20 peers (local-currency closes).

Hebei Changshan Biochemical Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥930MCN¥874MCN¥1.03BCN¥1.40BCN¥2.32B
Revenue growth—-15%-26%-40%—
Gross profitCN¥221MCN¥104MCN¥137MCN¥277MCN¥1.00B
EBITDAn/a-CN¥192M-CN¥128M-CN¥1.08BCN¥162M
Net income-CN¥351M-CN¥358M-CN¥249M-CN¥1.24BCN¥17.5M
Free cash flow-CN¥181M-CN¥71.7M-CN¥191M-CN¥206M-CN¥428M
Capital expenditureCN¥131MCN¥123MCN¥240MCN¥239MCN¥431M
Total debtCN¥2.61BCN¥2.63BCN¥2.58BCN¥2.37BCN¥2.53B

Quarterly statements and history in the cockpit →

Hebei Changshan Biochemical Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%RCUSLKFTVIMIAN302440PHVS300142BEAMCLDXZEALPVLAALMRXNCRMBX0283006887300255.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hebei Changshan Biochemical Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×5,000×10,000×RCUSVIMIAN302440300142BEAMCLDXZEALALMR300255.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hebei Changshan Biochemical Pharmaceutical is the large dot.

Hebei Changshan Biochemical Pharmaceutical competitors and peer comparison

Head to head with its named competitors (300255.SZ vs 002399.SZ vs 603707.SS vs SAN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Hebei Changshan Biochemical Pharmaceutical 300255.SZ$2.33B-59%0%-25%19.4×n/a
Shenzhen Hepalink Pharmaceutical 002399.SZ$1.80B-12%-6%8%2.1×-0.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SS$2.03B-3%+9%14%3.2×5.1%
Sanofi SAN.PA$114B+13%+15%27%2.6×-4.8%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%

How Hebei Changshan Biochemical Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hebei Changshan Biochemical Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300255.SZPeer medianRank in peer set
1-month return-14.5%-7.4%7th lowest of 21
6-month return-58.9%-10.8%lowest of 20
Distance from 52-week high-75.4%-35.0%lowest of 21
Revenue growth (TTM)+0.2%+10.7%7th lowest of 18
Operating margin-25.4%-13.6%7th lowest of 16
EV / Sales19.4×9.4×5th most expensive of 16
ROIC minus cost of capital-12.5 pp-6.1 pp4th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a

Questions

Who are Hebei Changshan Biochemical Pharmaceutical's main competitors?
Named competitors: Shenzhen Hepalink Pharmaceutical (002399.SZ), Nanjing King-Friend Biochemical Pharmaceutical (603707.SS), Sanofi (SAN.PA), Pfizer (PFE). The cockpit's measured peer set (industry) also includes Arcus Biosciences (RCUS), Lakefront Biotherapeutics (LKFT.AS), Vimian (VIMIAN.ST), SKBS (302440.KS), Pharvaris (PHVS), Walvax Biotechnology (300142.SZ).
Is Hebei Changshan Biochemical Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 19.4× against a peer median of 9.4×, 5th most expensive of 16 in its peer set.
How has Hebei Changshan Biochemical Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -58.9% against -10.8% for the median peer; over one year -69.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.